Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
JAMA Dermatol, 2022.
Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group.
Read publication: JAMA Dermatol
Related
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with mo...
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000...
Application of information theoretic feature selection and machine learning methods for the developm...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
0 Comments